Conduction disturbances and permanent pacemaker implantation after myval transcatheter heart valve or contemporary standard valves (Sapien and Evolut) implantation: insights from the LANDMARK Trial
J. Am. Coll. Cardiol; 84 (18 Suppl. B), 2024
BACKGROUND LANDMARK was a multicenter randomized trial that demonstrated noninferiority of the Myval balloon-expandable trans. catheter heart valve (THV) compared with the contemporary THVs (Sa- pien and Evolut series) at 30 days in patients with severe aortic stenosis. METHODS From January 2021 to Decem...